MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajo.2018.12.019

Медицинская библиотека · American journal of ophthalmology · 2019

Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.

Vegas-Revenga Nuria, Calvo-Río Vanesa, Mesquida Marina, Adán Alfredo, Hernández María Victoria, Beltrán Emma, Valls Pascual Elia, Díaz-Valle David, Díaz-Cordovés Gisela, Hernandez-Garfella Marisa, Martínez-Costa Lucía, Calvo Inmaculada, Atanes Antonio, Linares Luis F, Modesto Consuelo, González-Vela Carmen, Demetrio-Pablo Rosalia, Aurrecoechea Elena, Cordero Miguel, Domínguez-Casas Lucía C, Atienza-Mateo Belén, Martín-Varillas José Luis, Loricera Javier, Palmou-Fontana Natalia, Hernández José L, González-Gay Miguel A, Blanco Ricardo

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Cystoid macular edema (CME) is a leading cause of blindness. This study assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME.

DESIGN

Retrospective case series.

METHODS

Patients with CME secondary to noninfectious uveitis who had inadequate response to corticosteroids and at least 1 conventional immunosuppressive drug, and in most cases to other biological agents, were studied. CME was defined as central retinal thickness greater than 300 μm. The primary outcome measure was macular thickness. Intraocular inflammation, best-corrected visual acuity (BCVA), and corticosteroid-sparing effect were also analyzed.

RESULTS

A total of 25 patients (mean ± standard deviation age 33.6 ± 18.9 years; 17 women) with CME were assessed. Underlying diseases associated with uveitis-related CME are juvenile idiopathic arthritis (n = 9), Behçet disease (n = 7), birdshot retinochoroidopathy (n = 4), idiopathic (n = 4), and sarcoidosis (n = 1). The ocular patterns were panuveitis (n = 9), anterior uveitis (n = 7), posterior uveitis (n = 5), and intermediate uveitis (n = 4). Most patients had CME in both eyes (n = 24). TCZ was used in monotherapy (n = 11) or combined with conventional immunosuppressive drugs. Regardless of the underlying disease, compared to baseline, a statistically significant improvement in macular thickness (415.7 ± 177.2 vs 259.1 ± 499.5 μm; P = .00009) and BCVA (0.39 ± 0.31 vs 0.54 ± 0.33; P = .0002) was obtained, allowing us to reduce the daily dose of prednisone (15.9 ± 13.6 mg/day vs 3.1 ± 2.3 mg/day; P = .002) after 12 months of therapy. Remission was achieved in 14 patients. Only minor side effects were observed after a mean follow-up of 12.7 ± 8.34 months.

CONCLUSION

Macular thickness is reduced following administration of TCZ in refractory uveitis-related CME.

Для цитирования: Vegas-Revenga Nuria, Calvo-Río Vanesa, Mesquida Marina, Adán Alfredo, Hernández María Victoria, Beltrán Emma, Valls Pascual Elia, Díaz-Valle David, Díaz-Cordovés Gisela, Hernandez-Garfella Marisa, Martínez-Costa Lucía, Calvo Inmaculada, Atanes Antonio, Linares Luis F, Modesto Consuelo, González-Vela Carmen, Demetrio-Pablo Rosalia, Aurrecoechea Elena, Cordero Miguel, Domínguez-Casas Lucía C, Atienza-Mateo Belén, Martín-Varillas José Luis, Loricera Javier, Palmou-Fontana Natalia, Hernández José L, González-Gay Miguel A, Blanco Ricardo. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.. American journal of ophthalmology. 2019. DOI: 10.1016/j.ajo.2018.12.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.